Catheter-based endovascular celiac and hepatic denervation for type 2 diabetes: a multicenter, open-label, single-arm study.

ABSTRACT: Sympathetic hyperactivity is crucial driving factor for hyperglycemia in type 2 diabetes (T2D). We conducted a multicenter, open-label, single-arm trial to evaluate the safety and efficacy of endovascular denervation (EDN) targeting the celiac and hepatic arteries in patients with poorly controlled T2D, defined as glycated hemoglobin (HbA1c) > 7.5% and <10.5% despite treatment with metformin and at least one other antidiabetic agent (registered with the National Medical Products Administration of China and ClinicalTrials.gov, NCT05631561). A total of 37 patients were enrolled across three centers, and 30 patients underwent EDN between December 2022 and October 2023. Follow-up visits were conducted at 1, 3, 6, and 12 months. The primary endpoints were device- and/or procedure-related major

SUBMITTER: Wang Z 

PROVIDER: S-EPMC12615629 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature